nach oben

Erschienen in:

28.03.2022 | Nuclear Medicine

Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors

verfasst von: Guillaume Manson, Amaeshi Chukwunonye Lemchukwu, Fatima-Zohra Mokrane, Egesta Lopci, Nicolas Aide, Laetitia Vercellino, Roch Houot, Laurent Dercle

Erschienen in: European Radiology | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Abstract

The development of immunotherapy has revolutionized cancer treatment, improving the outcome and survival of many patients. Immune checkpoint inhibitors (ICIs), the most common form of immunotherapy, use antibodies to restore T-cells’ anti-tumor activity. Immune checkpoint inhibitors are gaining ground in the therapeutic strategy across various cancers. Although widely used in solid tumors, ICIs have shown remarkable efficacy in patients with Hodgkin lymphoma. 2-[¹⁸F]Fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET)/CT is the gold standard to stage and monitor responses in Hodgkin lymphoma. This article reviewed the use of 2-[¹⁸F]FDG-PET/CT in patients with Hodgkin lymphoma treated with ICI, focusing on image interpretation for response monitoring and detecting adverse events.

Key Points

• Immune checkpoint inhibitors have dramatically improved the outcome of patients with cancer. Their mechanisms of action induce inflammatory processes that might translate into a high 2-[ ¹⁸ F]FDG uptake visible on 2-[ ¹⁸ F]FDG-PET/CT, requiring an adaptation of the evaluation criteria.

• PET readers should be aware of new patterns of response observed with immunotherapy in assessing treatment response in HL patients.

• -[ ¹⁸ F]FDG-PET/CT has an unparalleled ability of assessing tumor response, visualizing signs of immune activation as well as immune-related adverse events in a one-stop-shop examination

Nur mit Berechtigung zugänglich

Chen R, Zinzani PL, Lee HJ et al (2019) Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087. Blood. 2019000324. https://doi.org/10.1182/blood.2019000324

Armand P, Engert A, Younes A et al (2018) Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol 36:1428–1439. https://doi.org/10.1200/JCO.2017.76.0793CrossRefPubMedPubMedCentral

Manson G, Mear J, Herbaux C et al (2019) Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. Eur J Cancer 115:47–56. https://doi.org/10.1016/j.ejca.2019.04.006CrossRefPubMed

Beköz H, Karadurmuş N, Paydaş S et al (2017) Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Oncol 28:2496–2502. https://doi.org/10.1093/annonc/mdx341CrossRefPubMed

Manson G, Brice P, Herbaux C et al (2020) Risk of relapse after anti-PD1 discontinuation in patients with Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-05015-2

Küppers R (2009) The biology of Hodgkin’s lymphoma. Nat Rev Cancer 9:15–27. https://doi.org/10.1038/nrc2542CrossRefPubMed

Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the warburg effect: the metabolic requirements of cell proliferation. Science (80-) 324:1029–1033CrossRef

Weiler-Sagie M, Bushelev O, Epelbaum R et al (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51:25–30. https://doi.org/10.2967/jnumed.109.067892CrossRefPubMed

Kumar A, Burger IA, Zhang Z et al (2016) Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: Prognostic significance of measurements in the coronal and transverse planes. Haematologica 101:1237–1243. https://doi.org/10.3324/haematol.2016.141846CrossRefPubMedPubMedCentral

10.

El-Galaly TC, D’Amore F, Mylam KJ et al (2012) Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 30:4508–4514. https://doi.org/10.1200/JCO.2012.42.4036CrossRefPubMed

11.

Jerusalem G, Beguin Y, Fassotte M et al (2001) Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin’s disease. Haematologica 86:266–273PubMed

12.

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067CrossRef

13.

Brice P, de Kerviler E, Friedberg JW (2021) Classical Hodgkin lymphoma. Lancet:6736. https://doi.org/10.1016/S0140-6736(20)32207-8

14.

Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586CrossRef

15.

Mokrane F-Z, Chen A, Schwartz LH et al (2020) Performance of CT compared with 18 F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology 18:192056. https://doi.org/10.1148/radiol.2020192056CrossRef

16.

Castello A, Grizzi F, Qehajaj D, Rahal D, Lutman F, Lopci E (2019) 18 F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. Leuk Lymphoma 60:367–375. https://doi.org/10.1080/10428194.2018.1488254

17.

Ansell SM (2019) Immunotherapy in Hodgkin lymphoma: the road ahead. Trends Immunol 40:380–386. https://doi.org/10.1016/j.it.2019.03.003CrossRefPubMed

18.

Ramchandren R, Domingo-Domènech E, Rueda A et al (2019) Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 Study. J Clin Oncol.19.00315. https://doi.org/10.1200/JCO.19.00315

19.

Manson G, Herbaux C, Brice P et al (2018) Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood 131:2856–2859. https://doi.org/10.1182/blood-2018-03-841262CrossRefPubMed

20.

Chen A, Mokrane F-Z, Schwartz LH et al (2020) Early 18 F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab. J Nucl Med 61:649–654. https://doi.org/10.2967/jnumed.119.232827CrossRefPubMed

21.

Dercle L, Seban R-D, Lazarovici J et al (2018) 18 F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti–programmed death 1 immune checkpoint inhibitor. J Nucl Med 59:15–24. https://doi.org/10.2967/jnumed.117.193011CrossRefPubMed

22.

Di Giacomo AM, Danielli R, Guidoboni M et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother 58:1297–1306. https://doi.org/10.1007/s00262-008-0642-yCrossRefPubMed

23.

Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33:3541–3543CrossRef

24.

Park HJ, Kim KW, Pyo J et al (2020) Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology 297:87–96. https://doi.org/10.1148/radiol.2020200443CrossRefPubMed

25.

Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50:1257–1260. https://doi.org/10.1080/10428190903040048

26.

Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128:2489–2496. https://doi.org/10.1182/blood-2016-05-718528CrossRefPubMed

27.

Merryman RW, Carreau NA, Advani RH et al (2020) Impact of treatment beyond progression with immune checkpoint blockade in Hodgkin lymphoma. Oncologist 25. https://doi.org/10.1634/theoncologist.2020-0040

28.

Grecea M, Marabelle A, Ammari S, Massard C, Champiat S (2020) Managing hyperprogressive disease in the era of programmed cell death protein 1/programmed death-ligand 1 blockade: a case discussion and review of the literature. Oncologist 25:369–374. https://doi.org/10.1634/theoncologist.2019-0671

29.

Champiat S, Ferrara R, Massard C et al (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 15:748–762CrossRef

30.

Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543. https://doi.org/10.1001/jamaoncol.2018.3676CrossRefPubMedPubMedCentral

31.

Wartewig T, Ruland J (2019) PD-1 tumor suppressor signaling in T cell lymphomas. Trends Immunol 40:403–414. https://doi.org/10.1016/j.it.2019.03.005CrossRefPubMed

32.

Wartewig T, Kurgyis Z, Keppler S et al (2017) PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature 552:121–125. https://doi.org/10.1038/nature24649CrossRefPubMedPubMedCentral

33.

Liput J, Guler E, Smith DA et al (2020) Clinical, imaging findings, responses, and outcomes of patients with classical Hodgkin lymphoma and non-Hodgkin lymphoma undergoing immune checkpoint inhibitor therapy: a single-institution experience. J Comput Assist Tomogr 44:619–626. https://doi.org/10.1097/RCT.0000000000001043CrossRefPubMed

34.

Seban R-D, Schwartz LH, Bonardel G, Dercle L (2020) Diagnosis of hyperprogressive disease in patients treated with checkpoint inhibitors using 18F-FDG PET/CT. J Nucl Med 61:1404–1405. https://doi.org/10.2967/jnumed.120.242768CrossRefPubMed

35.

Hiniker SM, Chen DS, Knox SJ (2012) Abscopal effect in a patient with melanoma. N Engl J Med 366:2035–2036. https://doi.org/10.1056/NEJMc1203984CrossRefPubMed

36.

Wight JC, Hawkes EA, Berlangieri SU, Khor R, Grigg AP (2018) An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma. Leuk Lymphoma 59:2749–2751. https://doi.org/10.1080/10428194.2018.1452217

37.

Michot JM, Mazeron R, Dercle L et al (2016) Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. Eur J Cancer 66:91–94. https://doi.org/10.1016/j.ejca.2016.06.017CrossRefPubMed

38.

Qin Q, Nan X, Miller T et al (2018) Complete local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin’s lymphoma. Radiat Res 190:322. https://doi.org/10.1667/rr15048.1CrossRefPubMedPubMedCentral

39.

Bernard-Tessier A, Baldini C, Castanon E et al (2020) Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunol Immunother 1–12. https://doi.org/10.1007/s00262-020-02647-z

40.

Tazdait M, Mezquita L, Lahmar J et al (2018) Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 88:38–47. https://doi.org/10.1016/j.ejca.2017.10.017CrossRefPubMed

41.

Thompson JA, Schneider BJ, Brahmer J et al (2020) Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 18:231–241. https://doi.org/10.6004/jnccn.2020.0012

42.

Mekki A, Dercle L, Lichtenstein P et al (2018) Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 96:91–104. https://doi.org/10.1016/j.ejca.2018.03.006CrossRefPubMed

43.

Dercle L, Mokrane F-Z, Schiano de Colella JM et al (2019) Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. Eur J Nucl Med Mol Imaging 46:1391–1392. https://doi.org/10.1007/s00259-019-04310-xCrossRefPubMed

44.

Ricciuti B, Genova C, De Giglio A et al (2019) Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. J Cancer Res Clin Oncol 145:479–485. https://doi.org/10.1007/s00432-018-2805-3CrossRefPubMed

45.

Haratani K, Hayashi H, Chiba Y et al (2018) Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer. JAMA Oncol 4:374–378. https://doi.org/10.1001/jamaoncol.2017.2925CrossRefPubMed

46.

Eggermont AMM, Kicinski M, Blank CU et al (2020) Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2019.5570

47.

Indini A, Di Guardo L, Cimminiello C et al (2019) Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 145:511–521. https://doi.org/10.1007/s00432-018-2819-xCrossRefPubMed

48.

Petrelli F, Grizzi G, Ghidini M et al (2020) Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis. J Immunother 43:1–7. https://doi.org/10.1097/CJI.0000000000000300CrossRefPubMed

49.

Sachpekidis C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, Hassel JC (2019) 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab. Melanoma Res 29:178–186. https://doi.org/10.1097/CMR.0000000000000541

50.

Sachpekidis C, Larribère L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A (2019) Can benign lymphoid tissue changes in 18 F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother 68:297–303. https://doi.org/10.1007/s00262-018-2279-9

51.

Nobashi T, Baratto L, Reddy SA et al (2019) Predicting response to immunotherapy by evaluating tumors, lymphoid cell-rich organs, and immune-related adverse events using FDG-PET/CT. Clin Nucl Med 44:e272–e279. https://doi.org/10.1097/RLU.0000000000002453CrossRefPubMed

52.

Wong A, Callahan J, Keyaerts M et al (2020) 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging 20:36. https://doi.org/10.1186/s40644-020-00313-2CrossRefPubMedPubMedCentral

53.

Aide N, Hicks RJ, Le Tourneau C et al (2019) FDG PET/CT for assessing tumour response to immunotherapy. Eur J Nucl Med Mol Imaging 46:238–250. https://doi.org/10.1007/s00259-018-4171-4CrossRefPubMed

54.

Seban R-D, Nemer JS, Marabelle A et al (2019) Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging 46:2298–2310. https://doi.org/10.1007/s00259-019-04411-7CrossRefPubMed

55.

Seban R-D, Synn S, Muneer I et al (2021) Spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development cannot be overlooked. Curr Cancer Drug Targets 21:944–952. https://doi.org/10.2174/1568009621666210720143826CrossRefPubMed

56.

Seban R-D, Champion L, Schwartz LH, Dercle L (2021) Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging 48:2309–2311. https://doi.org/10.1007/s00259-020-05126-wCrossRefPubMed

57.

Prigent K, Lasnon C, Ezine E et al (2021) Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. Eur J Nucl Med Mol Imaging 48:2573–2585. https://doi.org/10.1007/s00259-020-05103-3CrossRefPubMed

Titel: Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors
verfasst von: Guillaume Manson
Amaeshi Chukwunonye Lemchukwu
Fatima-Zohra Mokrane
Egesta Lopci
Nicolas Aide
Laetitia Vercellino
Roch Houot
Laurent Dercle
Publikationsdatum: 28.03.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 9/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-022-08669-8

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Impact of machine-learning-based coronary computed tomography angiography–derived fractional flow reserve on decision-making in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement

Interobserver agreement and prognostic impact for MRI–based 2018 FIGO staging parameters in uterine cervical cancer

CT-monitored minimal ablative margin control in single-session microwave ablation of liver tumors: an effective strategy for local tumor control

Development and validation of MRI-based radiomics signatures models for prediction of disease-free survival and overall survival in patients with esophageal squamous cell carcinoma

Development and validation of a composite AI model for the diagnosis of levator ani muscle avulsion

Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie